Novel anti-inflammatory peptides
Technology
First-in-class SLAMF1-derived peptides able to reduce TLR4-induced inflammation in response to a diverse set of stimuli (sterile and infectious).
Market
Broad application area with specific targets.
Acute and chronic inflammatory diseases.
Uniqueness
Therapeutic approach based on the discovery of novel targets and new mode of action.
No toxicity in human PBMc and lymphocytes in vitro.
Status
- Patent pending
- Pre-clinical stage
- Very promising in vitro and ex vivo data
- Promising pilot model of LPS-shock
- Animal studies currently being carried out
- Myocardial infarction
- Multiple myeloma
- Seeking commercial partners
